Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.695

Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients  

Pan, Jin-Bing (Department of Respiratory Medicine, Henan Provincial People's Hospital)
Hou, Yu-Hong (Department of Emergency, First Affiliated Hospital of Zhengzhou University)
Zhang, Guo-Jun (Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 695-700 More about this Journal
Abstract
Background: Mutations affecting the epidermal growth factor receptor (EGFR) are good predictors of clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer. Serum carcinoembryonic antigen (CEA) levels are also regarded as predictive for the efficacy of EGFR-TKI and EGFR gene mutations. This study analyzed the association between EGFR gene mutations and clinical features, including serum tumor marker levels in lung adenocarcinomas patients. Patients and Methods: A total of 70 lung adenocarcinoma patients with complete clinical data and pathological specimens were investigated. EGFR gene mutations at exons 19 and 21 were assessed. Serum tumor markers were detected by protein chip-chemiluminescence at the corresponding time, and correlations were analyzed. Results: Mutations of the EGFR gene were detected in 27 of the 70 patients and the serum CEA and CA242 concentrations were found to be significantly associated with the incidence of EGFR gene mutations (P<0.05). The AUCs for CEA and CA242 were 0.724 (95% CI: 0.598~0.850, P<0.05) and 0.769 (95% CI: 0.523~0.800, P<0.05) respectively. Conclusions: Serum CEA and CA242 levels are associated with mutations of the EGFR gene in patients with lung adenocarcinomas.
Keywords
Lung cancer; adenocarcinoma; epidermal growth factor receptor; tumor markers;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Addison CL, Ding K, Zhao H, et al (2010). Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol, 28, 5247-56.   DOI   ScienceOn
2 Bedi A, Pasricha PJ, Akhtar AJ, et al (1995). Inhibition of apoptosis during development of colorectal cancer. Cancer Res, 55, 1811-6.
3 Bronte G, Rizzo S, La Paglia L, et al (2010). Driver mutations and differential sensitivity to targeted therapies, a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev, 3, S21-9.
4 Cappuzzo F, Magrini E, Ceresoli GL, et al (2004). Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 96, 1133-41.   DOI   ScienceOn
5 Chen F, Luo X, Zhang J, et al (2010). Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Med Oncol, 27, 950-7.   DOI   ScienceOn
6 Costa DB, Kobayashi S, Tenen DG, et al (2007). Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 58, 95-103.   DOI   ScienceOn
7 Dong QG, Huang JS, Huang C, et al (2005). The progress at target therapy in lung cancer and EGFR gene mutation profile in China. (in Chinese). Tumors, 25, 625-8.
8 Dong QG, Huang JS, Yang LM, et al (2006). Epidermal growth factor receptor gene mutations in Chinese patients with adenocarcinoma of the lung. (in Chinese). Tumor 26, 271-5.
9 Duxbury MS, Ito H, Zinner MJ, et al (2004). CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene, 23, 465-73.   DOI   ScienceOn
10 Han C, Zou H, Ma J, et al (2010). Comparison of EGFR and KRAS statusbetween primary non-small cell lung cancer and corresponding metastases, a systematic review and meta-analysis. (in Chinese). Zhongguo Fei Ai Za Zhi, 13, 882-91.
11 Han R, Zhong W, Zhao J, et al (2011). Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma (in Chinese). Zhongguo Fei Ai Za Zhi, 14, 127-31.
12 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
13 Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.   DOI
14 Green MR (2004). Targeting targeted therapy. N Engl J Med, 350, 2191-3.   DOI   ScienceOn
15 Jiang H (2009). Overview of gefitinib in non-smallcell lung cancer, an Asian perspective. Jpn J Clin Oncol, 39, 137-50.
16 Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST), a randomised phase III trial. Lancet, 372, 1809-18.   DOI   ScienceOn
17 Kim TJ, Choi JJ, Kim WY, et al (2008). Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer. Cancer Sci, 99, 31-8.
18 Massarelli E, Andre F, Liu DD, et al (2003). A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer, 39, 55-61.   DOI   ScienceOn
19 Kosaka T, Yatabe Y, Endoh H, et al (2004). Mutations of the epidermal growth factor receptor gene in lung cancer, biological and clinical implications. Cancer Res, 64, 8919-23.   DOI   ScienceOn
20 Lamerz R (1999). Role of tumour markers, cytogenetics. Ann Oncol, 4, 145-9.
21 Miller VA, Kris MG, Shah N, et al (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9.   DOI   ScienceOn
22 Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.   DOI   ScienceOn
23 Mountain CF (1997). Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-7.   DOI   ScienceOn
24 Mu XL, LI LY, HE QY (2006). The diversity of epidermal growth factor receptor tyrosine kinase domain mutations and clinical features. (in Chinese). Tumor, 26, 956-9.
25 Okamoto T, Nakamura T, Ikeda J, et al (2005). Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer, 41, 1286-90.   DOI   ScienceOn
26 Ou G, Hedberg M, Horstedt P, et al (2009). Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. Am J Gastroenterol, 104, 3058-67.   DOI   ScienceOn
27 Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer, correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.   DOI   ScienceOn
28 Pfister DG, Johnson DH, Azzoli CG, et al (2004). American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline, update 2003. J Clin Oncol, 22, 330-53.
29 Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55,74-108.   DOI   ScienceOn
30 Park K, Goto K (2006). A review of the benefit-risk profile ofgefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin, 22, 561-73.   DOI   ScienceOn
31 Schiller JH, Harrington D, Belani CP, et al (2002). Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.   DOI   ScienceOn
32 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.   DOI   ScienceOn
33 Shoji F, Yoshino I, Yano T, et al (2007). Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer, 110, 2793-8.   DOI   ScienceOn
34 Sordella R, Bell DW, Haber DA, et al (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 305, 1163-7.   DOI   ScienceOn
35 Tsuchiya A, Koizumi M, Ohtani H (2009). World Health Organization Classification (2004)-based re-evaluation of 95 nonfunctioning "malignant" pancreatic endocrine tumors reported in Japan. Surg Today, 39, 500-9.   DOI   ScienceOn
36 Tufman A, Huber RM (2010). Biological markers in lung cancer, A clinician's perspective. Cancer Biomark, 6, 123-35.
37 Yin GH, Liu Wei, Wu Yong (2009). Epidermal growth factor receptor gene mutations in Chinese patients with primary lung adenocarcinoma. (in Chinese). Chin J Gerontol, 29, 443-5.
38 Yang SH, Mechanic LE, Yang P, et al (2005). Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res, 11, 2106-10.   DOI   ScienceOn
39 Yang X, Wang D, Li Z, et al (2007). Clinicalsignificance of multiple tumor marker protein chip in monitoring the recurrence, progression and metastasis of lung cancer. (in Chinese). Zhongguo Fei Ai Za Zhi, 10, 296-300.